It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Lung cancer is one of the most common reasons for cancer-induced mortality across the globe, despite major advancements in the treatment strategies including radiotherapy and chemotherapy. Existing reports suggest that CXCR4 is frequently expressed by malignant tumor and is imperative for vascularization, tumor growth, cell migration, and metastasis pertaining to poor prognosis. In this study, we infer that CXCR4 confers resistance to ionizing radiation (IR) in nonsmall cell lung cancer (NSCLC) cells. Further, on the basis of colony forming ability, one finds that drug-resistant A549/GR cells with improved CXCR4 expression exhibited more resistance to IR than A549 cells evidenced along with a reduction in the formation of γ-H2AX foci after IR. Transfection of shRNA against CXCR4 or treatment of pharmacological inhibitor (AMD3100) both led to sensitization of A549/GR cells towards IR. Conversely, the overexpression of CXCR4 in A549 and H460 cell lines was found to improve clonogenic survival, and reduce the formation of γ-H2AX foci after IR. CXCR4 expression was further correlated with STAT3 activation, and suppression of STAT3 activity with siSTAT3 or a specific inhibitor (WP1066) significantly stymied the colony-forming ability and increased γ-H2AX foci formation in A549/GR cells, indicating that CXCR4-mediated STAT3 signaling plays an important role for IR resistance in NSCLC cells. Finally, CXCR4/STAT3 signaling was mediated with the upregulation of Slug and downregulation of the same with siRNA, which heightened IR sensitivity in NSCLC cells. Our data collectively suggests that CXCR4/STAT3/Slug axis is paramount for IR resistance of NSCLC cells, and can be regarded as a therapeutic target to enhance the IR sensitivity of this devastating cancer.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Korea Institute of Radiological and Medical Sciences, Radiation Therapeutics Development Team, Division of Radiation Cancer Science, Seoul, Korea (GRID:grid.415464.6) (ISNI:0000 0000 9489 1588)
2 Korea Institute of Radiological and Medical Sciences, Radiation Therapeutics Development Team, Division of Radiation Cancer Science, Seoul, Korea (GRID:grid.415464.6) (ISNI:0000 0000 9489 1588); Korea University, School of Biomedical Science, Seoul, Korea (GRID:grid.222754.4) (ISNI:0000 0001 0840 2678)
3 Korea Institute of Radiological and Medical Sciences, Radiation Therapeutics Development Team, Division of Radiation Cancer Science, Seoul, Korea (GRID:grid.415464.6) (ISNI:0000 0000 9489 1588); Korea University, Department of Life Sciences, Seoul, Korea (GRID:grid.222754.4) (ISNI:0000 0001 0840 2678)
4 Korea Institute of Radiological and Medical Sciences, Division of RI Application, Seoul, Korea (GRID:grid.415464.6) (ISNI:0000 0000 9489 1588)
5 Daegu Catholic University, Department of Biochemistry, School of Medicine, Daegu, Korea (GRID:grid.412072.2) (ISNI:0000 0004 0621 4958)